← Back to headlines
Alx Oncology Presents Interim ASPEN-09 Clinical Trial Data
Alx Oncology has provided an update on interim data from its ASPEN-09 clinical trial, involving approximately 80 patients, with a focus on the CD47-high cohort showing a 22-month median progression-free survival.
9 May, 08:02 — 9 May, 08:02
Sources
Showing 1 of 1 sources
Related Stories
'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video
just now
Taal Volcano Exhibits Continued Seismic Activity After Minor Eruption
just now
The Science of Intuition: When to Trust Your Gut
41m ago
German Spider Researcher Advocates Welcoming Invasive Species
41m ago